RNA-transfected CD40-B Cell Vaccines for Dogs With Newly Diagnosed Lymphoma

May 4, 2015

Study: Clinical Advancement of RNA-transfected CD40-B Cell Vaccine Technology for Cancer Therapy

Enrollment Closed

This clinical trial is currently closed for enrollment.

Study Purpose:

The purpose of this study is to determine whether repeat vaccinations with a cancer vaccine, made from your dog’s own immune cells (B cells), can prevent relapse of lymphoma when given following a standard 19-week course of chemotherapy. 

If your dog is in remission after chemotherapy, he or she will receive three vaccinations, each given three weeks apart.  After this, dogs will be vaccinated every two months to try to prevent lymphoma relapse. 

There is no fee to participate in the study.  The costs for the clinic visits, vaccines and follow-up monitoring will be covered by the study.



  • Dogs with a confirmed diagnosis of either B or T cell lymphoma
  • Dogs who have not yet received any treatment for their lymphoma
  • Dogs that are systemically healthy at the time of diagnosis
  • Dogs that will undergo a standard 19-week course of chemotherapy
  • Dogs that are in clinical remission following chemotherapy


If you are interested in participating in this clinical trial or would like to learn more about it, please contact:

Dr. Nicola Mason

Learn more about Dr. Mason's canine cancer immunotherapy research...